How to Read a Cancer Diagnosis Report: Understanding Biopsy, TNM Staging & Markers

Reviewed by

Dr. Lovedeep Singh Chauhan MS, MCh (Surgical Oncology) | Senior Surgical Oncologist Trained at Tata Memorial Hospital, Mumbai Practicing at Max Super Speciality Hospital, Mohali This article is written for patient education purposes only and does not constitute personal medical advice.

Receiving a cancer diagnosis report is one of the most frightening moments a patient and family can face. The paper in your hands is filled with medical terms, numbers, abbreviations, and grading systems that mean nothing to most people — yet feel like they mean everything.

Patients from across Punjab — from Chandigarh and Mohali to smaller cities like Kurali and Ropar — often arrive at their first consultation holding a report they cannot understand, feeling lost and anxious. This guide is written specifically to help you make sense of what is written in your cancer diagnosis report, so you can have a more informed and confident conversation with your surgical oncologist in Punjab.

Understanding your report does not make you a doctor. But it does make you a better-informed patient — and that matters enormously when decisions about surgery, chemotherapy, or targeted therapy need to be made.

What Is a Cancer Diagnosis Report?

A cancer diagnosis report is a document produced by a pathologist — a specialist doctor who examines tissue samples under a microscope. It is the single most important document in your cancer journey because it tells your treating surgeon exactly what type of cancer is present, how aggressive it is, and how far it has spread.

There are two main types of reports you will commonly encounter. The first is a biopsy report, which is done before surgery to confirm the diagnosis. The second is a histopathology report, which is done after surgery on the removed tissue to give the complete final picture.

Both reports use similar language and grading systems. Once you understand the key sections, reading them becomes significantly less frightening.

Section 1: Understanding Your Biopsy Report

What Is a Biopsy?

A biopsy is a procedure where a small sample of tissue is taken from the suspected tumour and examined under a microscope. It is the only definitive way to confirm whether a lump, growth, or shadow on a scan is truly cancer or something else entirely.

There are several types of biopsies: fine needle aspiration (FNAC), core needle biopsy, incisional biopsy, and excisional biopsy. The type used depends on the location and size of the tumour. Each gives a slightly different amount of tissue for analysis.

What the Biopsy Report Tells You

The biopsy report will typically contain the following key findings:

• Malignant or Benign - This is the most fundamental finding. Malignant means cancerous — the cells are abnormal and have the potential to invade surrounding tissue or spread. Benign means non-cancerous — the growth is abnormal but contained and does not invade or spread. If your report says malignant, further staging and treatment planning begins immediately.
• Type of Cancer (Histological Type) - This tells you which type of cell the cancer originated from. Common examples include adenocarcinoma (arising from gland cells, common in colorectal cancers and gynaecological malignancies), squamous cell carcinoma (common in head and neck cancers), and papillary carcinoma (the most common type in thyroid/endocrine malignancies). The cell type determines which treatments will be most effective.
• Grade (Differentiation) - Tumour grade describes how abnormal the cancer cells look compared to normal cells and how fast they are likely to grow.
• Grade 1 (well-differentiated) means the cells still look somewhat normal and tend to grow slowly.
• Grade 2 (moderately differentiated) is intermediate.
• Grade 3 (poorly differentiated) means the cells look very abnormal and tend to be more aggressive.

Grade is not the same as stage — it tells you about behaviour, not spread.

Section 2: Understanding TNM Staging

What Is TNM Staging?

TNM staging is the international system used by oncologists worldwide to describe how far a cancer has spread in the body. It is the single most important factor in deciding treatment including whether surgery is the right first step, and if so, what kind.

TNM stands for three things: T for Tumour, N for Nodes, and M for Metastasis. Each is given a number, and together they determine the overall stage of the cancer from Stage I to Stage IV.

T - Tumour Size and Local Extent

The T category describes the size of the primary tumour and whether it has grown into nearby tissues:

• TX - The primary tumour cannot be assessed.
• T0 - No evidence of a primary tumour found.
• T1 - Small tumour, confined within the organ of origin, has not grown through the wall or into surrounding tissue.
• T2 - Tumour has grown slightly larger or into the deeper layers of the organ but has not broken through.
• T3 - Tumour has grown through the wall of the organ into surrounding fat or nearby tissue but has not reached adjacent organs.
• T4 - Tumour has grown directly into adjacent organs or structures — the most locally advanced category.

For example, in colorectal cancer surgery performed by Dr. Lovedeep Singh Chauhan, a T1 or T2 rectal tumour may be suitable for organ-preserving robotic surgery, while a T4 tumour may require more extensive resection and possibly pre-operative chemotherapy or radiation first.

N - Lymph Node Involvement

The N category tells you whether cancer cells have spread to nearby lymph nodes — the small glands that are part of your immune system:

• NX - Nearby lymph nodes cannot be assessed.
• N0 - No cancer found in any nearby lymph nodes — a very positive finding.
• N1 - Cancer found in 1–3 nearby lymph nodes.
• N2 - Cancer found in 4 or more nearby lymph nodes.

Lymph node involvement is one of the most critical prognostic factors. N0 disease generally carries a much better outlook than N1 or N2. It also directly influences whether chemotherapy is recommended after surgery.

M - Metastasis (Distant Spread)

The M category tells you whether cancer has spread to distant organs — the lungs, liver, bones, or brain:

• M0 - No distant spread detected. Cancer is localised or regional only.
• M1 - Cancer has spread to one or more distant organs.

M0 disease is generally treatable with surgery as a primary approach.

M1 disease - which is Stage IV cancer does not always mean surgery is not possible, but treatment planning becomes significantly more complex and individualised.

Overall Stage: Putting T, N, M Together

Once T, N, and M are assigned, the oncologist combines them into an overall stage:

• Stage I - Small tumour, no lymph node involvement, no distant spread. Most favourable outcomes with surgery.
• Stage II - Larger or more locally invasive tumour, but still no lymph node spread. Generally treated with surgery, sometimes followed by chemotherapy.
• Stage III - Tumour with regional lymph node involvement but no distant spread. Surgery combined with chemotherapy or radiation is typically the treatment approach.
• Stage IV - Distant metastasis present. Treatment is individualised — surgery may still be possible in selected patients depending on the type of cancer and extent of spread.

Section 3: Tumour Markers — What Are They?

What Is a Tumour Marker?

A tumour marker is a substance — usually a protein — that is produced by cancer cells or by the body in response to cancer. It is measured through a blood test. Tumour markers are used to support diagnosis, monitor treatment response, and detect recurrence after surgery.

It is important to understand that tumour markers alone do not diagnose cancer. An elevated marker must always be interpreted alongside imaging and biopsy results.

Common Tumour Markers and What They Mean

CEA (Carcinoembryonic Antigen) — Most commonly used in colorectal cancer. An elevated CEA before surgery, followed by a drop after surgery, confirms that the tumour was successfully removed. Rising CEA during follow-up may indicate recurrence.

CA-125 — Used in ovarian and other gynaecological malignancies. Elevated levels suggest active disease; monitoring CA-125 during treatment helps assess how well the therapy is working.

CA 19-9 — Associated with pancreatic and gastrointestinal cancers. Used to monitor treatment response rather than for initial diagnosis.

PSA (Prostate-Specific Antigen) — Used in urological malignancies, specifically prostate cancer. Elevated PSA prompts further investigation; post-treatment PSA monitoring is a standard part of prostate cancer follow-up.

Thyroglobulin — Used after thyroid surgery for endocrine malignancies. In patients who have had their thyroid removed, thyroglobulin should be undetectable. Any rise signals possible recurrence.

Her2/neu and ER/PR receptors — These are not classical tumour markers but receptor tests done on breast cancer tissue. They determine whether the cancer will respond to hormone therapy or targeted drugs like trastuzumab — a critical decision point in breast cancer treatment planning.

Section 4: Other Terms You Will See in Your Report

Surgical Margins — After surgery, the pathologist checks the edges of the removed tissue. Clear margins (also called negative margins or R0 resection) mean no cancer cells are present at the cut edges — the tumour was completely removed. Positive margins mean cancer cells are present at the edge, which may require further surgery or radiation.

Lymphovascular Invasion (LVI) — This means cancer cells have been found inside blood vessels or lymphatic channels near the tumour. LVI is a risk factor for spread and often influences the decision to recommend chemotherapy after surgery.

Perineural Invasion (PNI) — Cancer cells found growing along nerve fibres. Like LVI, this indicates more aggressive behaviour and affects post-surgical treatment recommendations.

Ki-67 Index — A measure of how rapidly the cancer cells are dividing. A high Ki-67 percentage means the cancer is growing quickly. This is particularly relevant in breast cancers and neuroendocrine tumours.

Immunohistochemistry (IHC) — A special staining technique used on tissue samples to identify specific proteins on cancer cells. IHC results determine the exact subtype of cancer and guide targeted treatment decisions. You will often see IHC panels listed in biopsy reports with "positive" or "negative" results next to various markers.

How Staging Guides Dr. Lovedeep Singh Chauhan's Surgical Decisions

Understanding staging is not just an academic exercise it directly shapes the surgical plan. For colorectal cancers, early-stage tumours may be treated with organ-preserving robotic surgery, while advanced stages may need neoadjuvant (pre-surgery) chemotherapy or radiation first. In gynaecological malignancies such as ovarian cancer, the stage determines whether primary debulking surgery or interval surgery after chemotherapy is the right approach

For head and neck cancers, staging tells the surgeon whether the lymph nodes need to be dissected and to what extent. For breast cancers, receptor status from the biopsy report determines whether surgery alone is sufficient or whether hormone therapy or targeted therapy must follow. For endocrine malignancies like thyroid cancer, the extent of lymph node dissection is guided directly by the T and N classification.

This is why arriving at your surgical consultation with a complete and clearly organised set of reports — biopsy, imaging, and tumour markers — is so important. [→ Read our Step-by-Step Guide to Preparing for Cancer Surgery to know exactly which reports to bring]

What to Do After Reading Your Report

Reading your report is the first step — acting on it correctly is what matters. Here is what to do once you have reviewed your findings:

Do not try to self-diagnose or self-stage based on internet searches alone. The same TNM numbers can mean very different things depending on the cancer type, your overall health, and available treatment options. Write down the key findings — tumour type, grade, T/N/M numbers, and any positive markers — and bring them to your consultation.

Ask your surgical oncologist to explain your report in plain language. You are fully entitled to understand your own diagnosis. A good oncologist will take the time to walk you through each finding and explain what it means for your treatment options. If something is unclear, ask again.

[→ Read our guide: What to Do After Receiving a Cancer Diagnosis — First 7 Steps Explained]

Read our reviews on google

Frequently Asked Questions (FAQs)

Disclaimer

This article is intended solely for general patient education and awareness. Cancer diagnosis reports contain complex medical information that must be interpreted by a qualified oncologist in the context of the patient's full clinical picture. The explanations provided in this guide are simplified for general understanding and do not constitute a substitute for professional medical interpretation of your specific report. Treatment decisions must always be made in direct consultation with your treating surgical oncologist. Dr. Lovedeep Singh Chauhan and this website do not claim guaranteed outcomes from any diagnosis, staging, or treatment pathway described here. Individual cases vary significantly based on cancer type, overall health, and many other clinical factors.